Drug Trial Radar · NCT03699124
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
Last checked: Nov 19, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,129
Actual
Start
Jun 19, 2019
Primary completion
Jan 6, 2020
Study completion Jun 22, 2020
Sponsor
- Lead sponsor
- Bavarian NordicIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Oct 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 3 multicenter trial to evaluate safety and immune response of three consecutive production lots of freeze-dried (FD) MVA-BN smallpox vaccine. The vaccine will be given to healthy subjects who do not have a smallpox scar. Approximately 1110 subjects will be randomly enrolled into one of three groups: Group 1 will include 370 subjects, who will receive two separate injections (shot) with a short needle, given below the skin of the upper arm with 0.5 mL FD MVA-BN (Lot 1). Group 2 will include 370 subjects, who will receive two separate injections (shot) with a short needle, given below the skin of the upper arm with 0.5 mL FD MVA-BN (Lot 2). Group 3 will include 370 subjects, who will receive two separate injections (shot) with a short needle, given below the skin of the upper arm with 0.5 mL FD MVA-BN (Lot 3). The primary objective of the trial is to show that the immune response elicited (produced) by three consecutively produced MVA-BN lots are statistically (numerically) comparable.
Conditions
- Smallpox
Interventions
FD MVA-BNBiological
Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vaccinia-Specific Neutralizing Antibodies Measured by Plaque Reduction Neutralization Test (PRNT)Time frame: Two weeks post second vaccination; approximately Week 6.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Optimal Research, LLC (Synexus)
Melbourne, Florida
Optimal Research, LLC (Synexus)
Peoria, Illinois
University of Iowa
Iowa City, Iowa
University of Kentucky Healthcare Chandler Hospital
Lexington, Kentucky
Optimal Research, LLC (Synexus)
Rockville, Maryland
Saint Louis University
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Rochester Clinical Research, Inc.
Rochester, New York
M3 Wake Research, Inc.
Raleigh, North Carolina
Lynn Health Science Institute
Oklahoma City, Oklahoma
Omega Medical Research
Warwick, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.